Clinical Trials
51 trialsA Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
M.D. Anderson Cancer Center
CUPem
Imperial College London
TraveraRTGx
Travera Inc
Sintilimab in Cancer of Unknown Primary
M.D. Anderson Cancer Center
CUPISCO
Hoffmann-La Roche
Genomic Testing and Resulting Medical Decisions
Arbeitsgemeinschaft medikamentoese Tumortherapie
ROOT
Taproot Health
CUP-COMP
The Christie NHS Foundation Trust
OP-CUP
Rigshospitalet, Denmark
HARE-40
University of Southampton
AGNOSTOS
Fondazione del Piemonte per l'Oncologia
Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study
Mayo Clinic
TOFFEE
University of Edinburgh
Postoperative Pain, Why Still in Hospital and DAOH Following TORS for SCCUP & OSAS
Rigshospitalet, Denmark
APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
Apollomics (Australia) Pty. Ltd.
Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary
Fudan University
Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary
Eastern Cooperative Oncology Group
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
University of Chicago
GEFCAPI04
Gustave Roussy, Cancer Campus, Grand Paris
E-MOSAIC Electronic Tool to Monitor Symptoms
Swiss Cancer Institute
EPAC
Stanford University
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
Montefiore Medical Center
Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
Foundation Medicine
Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor
European Organisation for Research and Treatment of Cancer - EORTC
PET Scans and CT Scans in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
Wake Forest University Health Sciences
Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin
St. Jude Children's Research Hospital
Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
Alliance for Clinical Trials in Oncology
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Alliance for Clinical Trials in Oncology
High-dose ICE With Amifostine
Dana-Farber Cancer Institute
Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer
University of Miami
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
OHSU Knight Cancer Institute
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
Valerio Therapeutics
Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Review of Molecular Profiling-Real Time Polymerase Chain Reaction (Rt-Pcr) in Unknown Primary Cancer
SCRI Development Innovations, LLC
Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer
Yale University
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.
Fox Chase Cancer Center
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
National Cancer Institute (NCI)
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Cost-effectiveness Study of miRviewâ„¢ Mets in Patients With Cancer of Unknown Primary (CUP)
Teva Branded Pharmaceutical Products R&D, Inc.
Gemox as First and Second Line Therapy in Unknown Primary Cancer
M.D. Anderson Cancer Center
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Positron Emission Tomography - Computed Tomography (PET-CT) Scan as a Diagnostic Method in Unknown Primary Tumors
Rigshospitalet, Denmark
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
National Cancer Institute (NCI)
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NYU Langone Health
Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity
NYU Langone Health
Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC